Courtesy of General Physician, PC

The U.S. Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant), a new non-hormonal medication developed by Bayer, for the treatment of moderate to severe hot flashes and night sweats associated with menopause. The approval signifies an important milestone for women seeking relief from these common, yet often debilitating, symptoms.

Unlike traditional hormone replacement therapy (HRT), Lynkuet works by blocking two brain receptors—neurokinin-1 and neurokinin-3—that control the body’s temperature regulation system. During menopause, decreasing estrogen levels can disrupt this system, causing sudden hot flashes. Phase III OASIS clinical trials showed that women taking Lynkuet once daily experienced significant reductions in the frequency and severity of hot flashes within 4 to 12 weeks, compared to those taking a placebo.

Dr. Brittany Keeler, DO, NCMP, an OBGYN physician practicing at Queen City OBGYN, says, “Many women cannot or prefer not to use hormones. Lynkuet offers an effective new alternative for managing menopausal symptoms.”

Lynkuet is taken once daily and is not a hormone. Possible side effects include fatigue, dizziness, and elevated liver enzymes. Those taking it should not be pregnant and should avoid grapefruit products. The medication is now available, with insurance coverage likely to expand as providers start using the new therapy. For Western New Yorkers, Lynkuet offers hope—and more control—over a natural stage of life that can finally feel a little less uncomfortable.

For information on whether Lynkuet is right for you, please don’t hesitate to contact Dr. Brittany Keeler, an OBGYN physician practicing at Queen City OBGYN, located at 5014 Transit Road, Depew, NY 14043, or call 716-748-4444. Visit https://www.gppconline.com/brittanny-keeler-do-ncmp and https://www.gppconline.com/specialties/Queen-City-OBGYN to learn more about Dr. Keeler and Queen City OBGYN.